Insmed Incorporated (NASDAQ:INSM) Shares Bought by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC lifted its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 522.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 747 shares of the biopharmaceutical company’s stock after acquiring an additional 627 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Insmed were worth $55,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. GAMMA Investing LLC grew its holdings in Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 224 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 287 shares during the period. EntryPoint Capital LLC bought a new stake in Insmed in the first quarter worth about $33,000. Fidelis Capital Partners LLC acquired a new stake in Insmed in the 1st quarter valued at about $34,000. Finally, CWM LLC boosted its position in shares of Insmed by 11.0% during the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 155 shares in the last quarter.

Insmed Price Performance

Shares of INSM opened at $71.94 on Thursday. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The firm has a market cap of $10.69 billion, a PE ratio of -13.76 and a beta of 1.11. The firm’s 50 day moving average price is $73.98 and its 200 day moving average price is $59.42. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million for the quarter, compared to analyst estimates of $87.95 million. The company’s revenue was up 17.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.78) earnings per share. As a group, research analysts expect that Insmed Incorporated will post -5.41 EPS for the current fiscal year.

Insider Transactions at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the transaction, the insider now directly owns 100,100 shares of the company’s stock, valued at approximately $7,157,150. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at $7,951,559.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of Insmed stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the sale, the insider now directly owns 100,100 shares in the company, valued at approximately $7,157,150. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,882 shares of company stock worth $5,765,446. 4.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently commented on INSM. The Goldman Sachs Group increased their target price on shares of Insmed from $74.00 to $102.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. Bank of America lifted their target price on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. JPMorgan Chase & Co. increased their price target on Insmed from $72.00 to $74.00 and gave the company an “overweight” rating in a research report on Thursday, October 3rd. TD Cowen boosted their price objective on Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, StockNews.com downgraded shares of Insmed from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.73.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.